Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EDIT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Drug: EDIT-401 | Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1/2 · NCT07894887 | Not yet recruiting |
| EDIT-101 | Leber Congenital Amaurosis 10 | Phase 1/2 · NCT03872479 | Unknown |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EDIT holds $190.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.4M/quarter from operations, an estimated runway of 22.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 43 · Elevated
We expect that our existing cash, cash equivalents, and marketable securities on September 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2028 .10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EDIT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Commodore Capital LP | Institution (13G, 5%+) | 16,045,802 | 10.40% | 2026-05-26 |
| TCG Crossover GP III, LLC | 5%+ holder (13G) | 15,798,999 | 10.24% | 2026-05-27 |
| BlackRock, Inc. | Institution (13G, 5%+) | 11,937,882 | 7.73% | 2026-09-30 |
| TCG Crossover Management, LLC | Institution (13F) | 11,111,111 | 7.20% | 2026-09-30 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 8,889,000 | 5.76% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 8,889,000 | 5.76% | 2026-05-27 |
| Paradigm Biocapital Advisors LP | Institution (13F) | 7,575,140 | 4.91% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 7,038,580 | 4.56% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 6,073,405 | 3.94% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 4,681,324 | 3.03% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 3,888,523 | 2.52% | 2026-09-30 |
| Gilmore Neil O'Neill CEO, Director · +1.02M options |
Insider | 265,592 | 0.17% | 2026-11-11 |
Share count 154,339,748 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-11 filed 2026-11-13 |
Burkly Linda |
Sale (S) | 7,814 | $2.42 | 70,379 |
| 2026-11-11 filed 2026-11-13 |
O'Neill Gilmore Neil |
Sale (S) | 21,164 | $2.42 | 265,592 |
| 2026-11-05 filed 2026-11-06 |
O'Neill Gilmore Neil |
Award (A) | 43,567 | – | 286,756 |
| 2026-11-05 filed 2026-11-06 |
Burkly Linda |
Award (A) | 16,533 | – | 78,193 |
| 2026-09-08 filed 2026-09-09 |
Ory Daniel Scott |
Option award (A) | 950,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EDIT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →